Pancreatic ductal adenocarcinoma (PDAC) · line 1 · Olaparib maintenance (BRCA-mut PDAC post-platinum, POLO)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-OLAPARIB-MAINT-PDAC`

ID	`IND-PDAC-MAINTENANCE-OLAPARIB-BRCA`
Type	Indication
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-PDAC`
Sources	`SRC-ESMO-PANCREATIC-2024` `SRC-NCCN-PANCREATIC-2025`

Notes

BRCA-germline maintenance — follows FOLFIRINOX/gem-cis induction with platinum response.

Used By

Algorithms

ALGO-PDAC-METASTATIC-1L - ALGO-PDAC-METASTATIC-1L
ALGO-PDAC-METASTATIC-2L - ALGO-PDAC-METASTATIC-2L

Indication

IND-PDAC-METASTATIC-2L-NAL-IRI - IND-PDAC-METASTATIC-2L-NAL-IRI